pharmacology

"The ISPE Glossary of Pharmaceutical and Biotechnology Terminology is the result of many years of gathering material from sources such as scientific journals, industrial magazines, professional organizations, the world wide web, industry seminars, company guides, vendor and manufacturer information, national and international codes, and diverse individuals. This compilation of abbreviations, acronyms, and terminology is a reference for engineers, designers, technicians, owners, contractors, and others in the pharmaceutical and biopharmaceutical industries.

"This dictionary contains more than three thousand terms that designate the most widely used drugs with names in Catalan and equivalents in Spanish, French and English, in addition to the registered number CAS and their mechanisms of action and therapeutic actions the most common, which can also be accessed via the Access theme. the nomenclature is updated annually to incorporate new international nonproprietary names of drugs approved that are available separately in the section new additions.

"Among the features of this third edition of the thesaurus are: (1) Listing of new or not previously listed pharmaceuticals from the above countries. (2) Listing of new uses for previously identified pharmaceuticals. It should be noted that pharmaceutical usages as indicated in this thesaurus are those indicated in the literature of the countries involved, and do not necessarily coincide with US usage of the same compound. (3) Listing of country of origin of both new and previously identified pharmaceuticals whenever possible.

"The Genomic Clinical Decision Support (Genomic CDS) project aims to create and maintain an integrated, ontology-based knowledge base of clinically relevant pharmacogenomic information. This knowledge base is used to implement clinical decision support algorithms for improving quality of care, e.g., for providing drug dosage recommendations and comparisons of the efficacy of different treatment options."

"The goal of DDI project is to develop an ontology for the description of drug discovery investigations. The Pharmaceutical industry is an information based industry. The aim of DDI is to add value to the information generated in the drug pipeline by making the information easier to reuse, integrate, curate, retrieve, and reason with. DDI aims to follow to the Open Biomedical Ontologies Foundry (OBO) principles, to use relations laid down in the OBO Relation Ontology, and to be compliant with Ontology for biomedical investigations (OBI)."

"In the Anatomical Therapeutic Chemical (ATC) classification system, the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. Drugs are classified in groups at five different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/therapeutic subgroups (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance.

"In the Anatomical Therapeutic Chemical (ATC) classification system, the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. Drugs are classified in groups at five different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/therapeutic subgroups (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance.